Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial ...

AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration ...

Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic ...

Absci has built a leading generative AI Drug Creation platform for therapeutic antibodies and we’re excited to bring this expertise into animal health,” said Sean McClain, Founder and CEO of Absci.

Absci (ABSI) and Invetx announced a strategic partnership to harness Absci’s AI Drug Creation models to create an innovative Half-Life ...

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.